Assessment of a retrospective drug utilization review alert letter program

Journal of Clinical Outcomes Management

Volumn 11, Issue 3, 2004, Pages 150-154

  Gleason, Patrick P ^a,b   Solberg, Christine L ^a   Brelje, Timothy V ^a   Hartwig, Steven C ^a   Wadd, Wallace ^a  

^a Prime Therapeutics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METFORMIN;

CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG UTILIZATION; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEART FAILURE; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; METABOLIC ACIDOSIS; PHARMACY; POSTAL MAIL; PRESCRIPTION; PRIVATE HEALTH INSURANCE; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNITED STATES; UTILIZATION REVIEW;

EID: 2942516146     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Medicaid program; Drug Use Review program and electronic claims management system for outpatient drug claims-HCFA. Interim final rule with comment period. Fed Regist 1992;57: 49397-412.
2. Lipton HL, Bird JA. Drug utilization review: state of the art from an academic perspective. Clin Pharmacol Ther 1991;50 (5 Pt 2):616-9.
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
4. Collins TM, Mott DA, Bigelow WE, Zimmerman DR. A controlled letter intervention to change prescribing behavior: results of a dual-targeted approach. Health Serv Res 1997; 32:471-89.
5. Smith DH, Christensen DB, Stergachis A, Holmes G. A randomized controlled trial of a drug use review intervention for sedative hypnotic medications. Med Care 1998;36:1013-21.
6. Guo JJ, Gibson JT, Hancock GR, Barker KN. Retrospective drug utilization review and the behavior of Medicaid prescribers: an empirical marginal analysis. Clin Ther 1995;17:1174-87.
7. Rascati KL, Okano GJ, Burch C. Evaluation of physician intervention letters. Med Care 1996;34:760-6.
8. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. JAMA 2002;287:2504-5.
9. Metformin [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2001.
10. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6.
11. Soumerai SB, McLaughlin TJ, Avorn J. Quality assurance for drug prescribing. Qual Assur Health Care 1990;2:37-58.
12. Wickizer TM. The effect of utilization review on hospital use and expenditures: a review of the literature and an update on recent findings. Med Care Rev 1990;47:327-63.
13. Soumerai SB, Lipton HL. Computer-based drug-utilization review-risk, benefit, or boondoggle? N Engl J Med 1995;332: 1641-5.
14. Hennessy S, Bilker WB, Zhou L, et al. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003;290:1494-9.
15. Berringer R, Friedla E, Rich K. Evaluation of drug utilization review programs. JAMA 2004;291:184-5.
16. Peng CC, Glassman PA, Marks IR, et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 2003;9:513-22.
17. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2002;(2):CD002967.
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003;163:2594-602.
19. American Diabetes Association. Standards of medical care in diabetes, Diabetes Care 2004;27(Suppl 1):S15-S35.
20. Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months' experience with use of metformin for type 2 diabetes mellitus in a large health maintenance organization. Diabetes Care 1999;22:38-44.